{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:12:30Z","timestamp":1789567950622,"version":"build-2803163510"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec id=\"ab-dbr250001-4\"><jats:title>Importance<\/jats:title><jats:p>VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease caused by <jats:italic>UBA1<\/jats:italic> somatic variants in hematopoietic progenitor cells, mostly involving adult men. It is associated with inflammatory-related symptoms, frequently involving the skin and hematological disorders. Recently described myelodysplasia cutis (MDS-cutis) is a cutaneous manifestation of myelodysplasia in which clonal myelodysplastic cells infiltrate the skin. In both cases, skin lesions are driven by the infiltration of clonal mutated myeloid cells and may clinically and histologically mimic Sweet syndrome (SS), a neutrophilic skin disease.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250001-5\"><jats:title>Objective<\/jats:title><jats:p>To decipher the underlying mechanisms driving these 3 myeloid-related skin diseases (ie, VEXAS, MDS-cutis, and SS) compared with leukemia cutis (LC), a neoplastic blastic myeloid-related skin condition, and healthy control skin samples.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250001-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter translational study on formaldehyde-fixed paraffin-embedded lesional skin samples of VEXAS syndrome, MDS-cutis, idiopathic SS, LC, and healthy controls using bulk RNA sequencing analyses was conducted in France. Patients included had cutaneous lesions of VEXAS syndrome, MDS-cutis, idiopathic SS, or LC. The data were analyzed from June 2023 to March 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250001-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Differentially expressed genes between conditions were studied. These genes were used to characterize the enrichment in activated inflammatory pathways in each condition using Gene Set Enrichment Analysis and Ingenuity Pathway Analysis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250001-8\"><jats:title>Results<\/jats:title><jats:p>Twenty patients with skin conditions (median [range] age, 67 [43-88] years; 10 [50%] men) were included. Six had cutaneous lesions of VEXAS syndrome, 4 had MDS-cutis, 5 had idiopathic SS, and 5 had LC. They were compared with 5 healthy control skin samples. Bulk RNA sequencing analysis reveals that MDS-cutis and VEXAS syndrome lesions display closely related transcriptomic profiles, highly imprinted by cytokine responses, interferon signatures, and activation of the apoptosis pathway. A shared inflammatory environment between MDS-cutis, VEXAS syndrome, and idiopathic SS was observed, mostly relying on a type 1 immune response led by type 1 and 2 interferons, along with the activation of tumor necrosis factor and interleukin (IL)\u20131\u03b2 pathways. Conversely, LC showed an isolated transcriptomic profile mainly enriched in cell cycle pathways.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250001-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this translational study highlight a common inflammatory pattern shared between VEXAS syndrome, MDS-cutis, and refractory idiopathic SS skin samples. This suggests the potential therapeutic targeting of interferon pathways in patients affected with refractory nonblastic myeloid-related skin diseases.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.0034","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:00:59Z","timestamp":1741791659000},"page":"538","source":"Crossref","is-referenced-by-count":9,"title":["Inflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome"],"prefix":"10.1001","volume":"161","author":[{"given":"Chlo\u00e9","family":"Grolleau","sequence":"first","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"},{"name":"Saint-Louis Research Institute, INSERM U976\u2013HIPI Unit, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Pathology Department, H\u00f4pital Saint Louis, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Zakine","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Poisot","sequence":"additional","affiliation":[{"name":"Saint-Louis Research Institute, INSERM U976\u2013HIPI Unit, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cordoliani","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mahevas","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Centre Hospitalo-Universitaire Saint-Antoine, Service de M\u00e9decine Interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[{"name":"National Referral Center for Rare Systemic Autoimmune Diseases, Universit\u00e9 Paris Descartes, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Georgin","family":"Lavialle","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Tenon, Sorbonne Universit\u00e9, Service de M\u00e9decine Interne, Centre de R\u00e9f\u00e9rence des Maladies Auto-Inflammatoires et des Amyloses d\u2019Origine Inflammatoire (CEREMAIA); H\u00f4pital Trousseau, Universit\u00e9 Pierre-et-Marie-Curie (UPMC)-Paris 6, Inserm UMRS_933, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie S\u00e9niors, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris et Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie S\u00e9niors, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris et Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Pierre","family":"Zhao","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie S\u00e9niors, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris et Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Serror","sequence":"additional","affiliation":[{"name":"Plastic Surgery Department, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Duchmann","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Saint Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Unit\u00e9 944\/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Clappier","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Saint Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Unit\u00e9 944\/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Onifarasoaniaina","sequence":"additional","affiliation":[{"name":"Institut Cochin, INSERM U1016, CNRS UMR8104, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Le Buanec","sequence":"additional","affiliation":[{"name":"Saint-Louis Research Institute, INSERM U976\u2013HIPI Unit, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moguelet","sequence":"additional","affiliation":[{"name":"Pathology Department, H\u00f4pital Tenon, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-David","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint Louis Hospital, Paris, France"},{"name":"Saint-Louis Research Institute, INSERM U976\u2013HIPI Unit, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Chasset","sequence":"additional","affiliation":[{"name":"Service de Dermatologie et Allergologie, Facult\u00e9 de M\u00e9decine, Sorbonne Universit\u00e9, H\u00f4pital Tenon, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Sorbonne Universit\u00e9, Inserm, Centre d\u2019Immunologie et des Maladies Infectieuses, CIMI-Paris, F-75013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FRENVEX Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"27","key":"dbr250001r1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease.","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"dbr250001r2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"issue":"2","key":"dbr250001r3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jaad.2020.02.048","article-title":"Risk of malignancy in histiocytoid Sweet syndrome: a systematic review and reappraisal.","volume":"83","author":"Haber","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"dbr250001r4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fimmu.2019.00414","article-title":"Insights into the pathogenesis of Sweet\u2019s syndrome.","volume":"10","author":"Heath","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"dbr250001r5","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.jid.2019.12.040","article-title":"Next-generation sequencing in myeloid neoplasm-associated Sweet\u2019s syndrome demonstrates clonal relation between malignant cells and skin-infiltrating neutrophils.","volume":"140","author":"Passet","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"8","key":"dbr250001r6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2021013967","article-title":"Clinical, pathological, and molecular features of myelodysplasia cutis.","volume":"139","author":"Delaleu","year":"2022","journal-title":"Blood"},{"issue":"11","key":"dbr250001r7","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","article-title":"UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome.","volume":"157","author":"Zakine","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dbr250001r8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jaad.2022.10.052","article-title":"Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59 cases.","volume":"88","author":"Zakine","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"dbr250001r9","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1038\/jid.2015.146","article-title":"Myelodysplasia cutis versus leukemia cutis.","volume":"135","author":"Osio","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"4","key":"dbr250001r10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a validated interferon score using NanoString technology.","volume":"38","author":"Kim","year":"2018","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"dbr250001r11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation.","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"dbr250001r12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0190-9622(98)70266-X","article-title":"Sweet\u2019s syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines?","volume":"39","author":"Giasuddin","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"dbr250001r13","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies.","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"dbr250001r14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2830948\/jamadermatology_grolleau_2025_br_250001_1747728385.30685.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:00:37Z","timestamp":1747839637000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2830948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.0034","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}